Showing 5461-5470 of 5771 results for "".
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Novartis to Cut Over 2000 Jobs in Switzerland, UKhttps://modernod.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/Novartis announced that it will slash more than 2,000 jobs by 2022, including eliminating 1,700 positions in Switzerland and around 400 roles in the UK, as it looks to increase profitability. The move comes as the company consolidates manufacturing and shifts positions elsewhere as part of plans
- Cigna Now Covering Avedro’s FDA-Approved Cross-Linking Procedurehttps://modernod.com/news/cigna-now-covering-avedros-fda-approved-cross-linking-procedure/2479851/Avedro announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa drug formulations and the KXL System used in the treatment of progressive keratoconus. Other health plans rec
- Ellex 2RT Retinal Rejuvenation Effective for Select Cases of Intermediate AMDhttps://modernod.com/news/ellex-2rt-retinal-rejuvenation-effective-for-select-cases-of-intermediate-amd/2479852/Ellex Medical Lasers Limited announced the results of the Ellex 2RT Laser Intervention in Age-Related Macular Degeneration (LEAD) multicenter clinical trial. The results of the trial were published in Ophthalmology. According to researchers involved in the LEAD trial, Ellex’s 2RT
- MacuLogix Launches the AdaptDx in Europehttps://modernod.com/news/maculogix-launches-the-adaptdx-in-europe-at-euretina/2479856/MacuLogix will launch the AdaptDx in Europe during its debut at the European Society of Retina Specialists (EURETINA) annual congress
- Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-enrolls-first-patient-in-phase-1-clinical-trial-evaluating-thr-687-for-treatment-of-dme/2479860/Oxurion announced the enrollment of the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME). THR-687 is a novel pan-RGD integrin antagoni
- Nidek Launches the GS-1 Gonioscopehttps://modernod.com/news/nidek-launches-the-gs-1-gonioscope/2479862/Nidek has announced the launch of the GS-1 Gonioscope. The GS-1 is the first automated gonioscopy device enabling 360-degree color iridocorneal angle imaging allowing more clinicians to reliably perform gonioscopy in
- Oxurion Enrolls First Patient in Phase 2 Study Evaluating THR-317 for Treatment of Idiopathic Macular Telangiectasia Type 1https://modernod.com/news/oxurion-enrolls-first-patient-in-phase-2-study-evaluating-thr-317-for-treatment-of-idiopathic-macular-telangiectasia-type-1/2479863/Oxurion, formerly ThromboGenics, announced that it has enrolled the first patient in a phase 2 open-label multicenter study evaluating the efficacy and safety of intravitreal THR-317, an anti-PIGF (human placental growth factor) antibody, for the treatment of Macular Telangiectasia Type 1 (MacTel
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- IOT Launches New Corporate Brandinghttps://modernod.com/news/iot-launches-new-corporate-branding/2479870/Optical technology company IOT has announced a change in brand identity as part of an overall strategy to better communicate its culture, values, and approach to market. The new website and social media profiles are designed to help the company share optical knowledge as well as information abou